Phase 2 of the AASK trial is presented here. Phase 1 of the trial showed that the use of ACE-inhibitors in African-American patients with hypertension and minimal proteinuria was superior at preventing the development of ESRD than beta-blockade or use of dihydropyridines. Phase 2 analyzes this data over a 10-year follow-up period.

***Note: Comments about this teaching resource, its content, and your thoughts can be made on this website (by registered users) or on Facebook (all users).


Time Required (estimated): 60 minutes
Title: AASK Trial
Author: Sarath Kolluru, MD
Author Type: Fellow
Citation: Nephrology On-Demand 2011
Date Created: 2011
Revisions: None Indicated
Disclaimers: None Indicated
Resource Type: Video
Recommend to a Colleague/Friend
Review this teaching resource below


To view the interactive video, click here
To view this video using an iPad or iPhone, see below

Transparent Peer Review
Your reviews are anonymous

GD Star Rating

To learn more about our 6-point transparent peer review system, click here



More in General Nephrology, Grand Rounds, Hypertension (76 of 226 articles)